In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alvogen Expands In CEE With Exeltis Portfolio

Executive Summary

Alvogen has struck a deal with Insud’s Exeltis to gain rights to 23 women’s healthcare brands in Russia, Ukraine and Kazakhstan.

You may also be interested in...



Alvogen Advances Its Branded Offering Via Agreements

By licensing Covis’ Alvesco ciclesonide inhaler in central and eastern Europe, as well as preparing to launch thee Qysmia weight-loss brand for which it just obtained approval in Korea, Alvogen is expanding its portfolio of branded drugs.

Last Year’s Winners Build On Successes

Firms that achieved recognition at last year’s Global Generics & Biosimilars Awards have continued to build on that success in the months since.

Alvogen Targets Esmya With First European Rival

Alvogen has gained European approvals for a rival to Gedeon Richter’s Esmya through the decentralized procedure.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel